"When Bezi Belete walks into work at the Cell Therapy Launch Facility on Bayer's Berkeley campus, the buzz of energy is palpable. Not only are she and the others working there setting new global benchmarks for cell therapy manufacturing, but they have the potential to provide a future treatment option for people living with Parkinson's disease. The number of people diagnosed with PD has doubled over the past 25 years to more than 10 million people worldwide."
"Someone very dear to me is living with Parkinson's disease, and I see the impact the disease has on their daily life, said Belete, who works on cell therapy quality. When I'm at work alongside all my colleagues, I know we're doing something to help that could make a significant impact for people who are living with Parkinson's and their caregivers."
Researchers and technicians at Bayer's Cell Therapy Launch Facility in Berkeley are advancing cell therapy manufacturing and developing potential treatments for Parkinson's disease. The number of people diagnosed with Parkinson's has doubled in 25 years to over 10 million worldwide. Bezi Belete works on cell therapy quality and cites a personal connection to the disease, motivating her work. On Sept. 22 a first participant received randomized treatment in the pivotal Phase 3 clinical trial of bemdaneprocel. Bemdaneprocel was created by BlueRock Therapeutics and is being developed with Bayer's biotech team. If approved, the therapy would be manufactured in Berkeley, where local policies support long-term innovation.
Read at www.berkeleyside.org
Unable to calculate read time
Collection
[
|
...
]